Replies to post #130087 on Biotech Values

[DewDiligence]

…but 10 cents per share profit in less than a quarter seems like far too much to have included in guidance [had it been for Lovenox].

Agreed.

[DewDiligence]

Teva’s undisclosed big product launch could be—and probably is—Lipitor. I.e. Teva could have a cut a deal with Ranbaxy to utilize Ranbaxy’s 180 days of H-W exclusivity, which is much too valuable an asset to waste.